Abstract:Diagrammatic sketch for the action of madecassic acid treatment on the RANKL/RANK signaling pathway during osteoclast differentiation and bone resorption. Madecassic acid modulates osteoclast differentiation and bone resorption through the RANKL‐induced NF‐κB, JNK, and NFAT pathways. The red arrows indicate either downregulation or inhibition of osteoclasts. IκBα, inhibitor of κBα; JNK, c‐Jun N‐terminal kinase; NFATc1, nuclear factor of activated T cells 1; NF‐κB, nuclear factor‐κB; p‐JNK, phosphorylated JNK; RANK, receptor activator of nuclear factor‐κB; RANKL, RANK ligand; TRAP, tartrate‐resistant acid phosphatase. Background Overproduction and activation of osteoclasts result in various bone diseases, such as osteoporosis, Paget's disease, and rheumatoid arthritis. Thus, inhibiting osteoclast formation and overactivation may effectively prevent osteoclast‐related bone diseases, especially osteoporosis. Madecassic acid, one of the most important active ingredients in Centella asiatica, has various biological effects, but its role in osteoclastogenesis remains unknown. Methods RAW 264.7 cells were stimulated with receptor activator of nuclear factor (NF)‐κΒ ligand (RANKL, 25 ng/mL) to differentiate into multi‐nucleated osteoclasts. Subsequently, osteoclasts were treated with or without varying concentrations of madecassic acid (1, 2.5, 5, and 10 μmol/L). Results Madecassic acid significantly inhibited RANKL‐induced osteoclastogenesis in a concentration‐dependent manner. In addition, it reduced the percentage of bone resorptive area compared with the control, confirming that madecassic acid can inhibit osteoclast function. Furthermore, luciferase reporter gene studies indicate that madecassic acid could decrease the transcriptional activity of NF of activated T cells (NFAT) and NF‐κB in a dose‐dependent manner. Quantitative real‐time polymerase chain reaction results show that madecassic acid attenuated the expression of osteoclast‐associated genes, including V‐ATPase‐d2, cathepsin K, tartrate‐resistant acid phosphatase (TRAP), NFAT cytoplasmic 1 (NFATc1). Western blot analysis shows that madecassic acid inhibited RANKL‐mediated degradation of IκBα and NFATc1 expression, as well as phosphorylation of c‐Jun N‐terminal kinase (JNK) in RAW 264.7 cells. Conclusion Madecassic acid inhibited osteoclast formation and function in vitro by suppressing NF‐κB, JNK, and NFAT signaling pathways, indicating its potential as a novel drug for the treatment of osteoclast‐related bone diseases, especially osteoporosis.

Madecassoside Inhibits Estrogen Deficiency‐induced Osteoporosis by Suppressing RANKL‐induced Osteoclastogenesis

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

Rat Chondrocyte Inflammation and Osteoarthritis Are Ameliorated by Madecassoside

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

Madecassic acid suppresses osteoclast differentiation and bone resorption by inhibiting RANKL‐induced NF‐κB, JNK and NFAT signaling pathways

Astilbin Prevents Bone Loss in Ovariectomized Mice Through the Inhibition of RANKL‐induced Osteoclastogenesis

Matrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-induced Osteoclastogenesis

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Maslinic Acid Suppresses Osteoclastogenesis And Prevents Ovariectomy-Induced Bone Loss By Regulating Rankl-Mediated Nf-Kappa B And Mapk Signaling Pathways

Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF-B signalling pathway and NFATc1 activity

Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity

Anti-Osteoporotic Activity of an Edible Traditional Chinese Medicine Cistanche deserticola on Bone Metabolism of Ovariectomized Rats Through RANKL/RANK/TRAF6-Mediated Signaling Pathways

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis <i>via</i> Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation

Damascenone Inhibits Osteoclastogenesis by Epigenetically Modulating Nrf2-Mediated ROS Scavenge and Counteracts OVX-Induced Osteoporosis

Protective Effect Of Acteoside On Ovariectomy-Induced Bone Loss In Mice

Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats via MAPK signaling

Cistanche Deserticola Polysaccharide Attenuates Osteoclastogenesis and Bone Resorption Via Inhibiting RANKL Signaling and Reactive Oxygen Species Production.

Tectoridin Inhibits Osteoclastogenesis and Bone Loss in a Murine Model of Ovariectomy-Induced Osteoporosis